List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines |
Others observations: Losartan can be used as an alternative for treatment of adults with hypertension for those patients in whom ACEi are indicated but not tolerated, specifically due to the presence of adverse events (mainly cough); including the sub-population of hypertensive patients associated with type II diabetes with proteinuria. |
Bolivia | LINAME 2011 - 2013 | No observations |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) |
WHO Model List of Essential Medicines (2021) | 12.4. Medicines used in heart failure |
Others observations: Therapeutic alternatives: 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain). |
List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines |
Others observations: Losartan can be used as an alternative for treatment of adults with hypertension for those patients in whom ACEi are indicated but not tolerated, specifically due to the presence of adverse events (mainly cough); including the sub-population of hypertensive patients associated with type II diabetes with proteinuria. |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) |
WHO Model List of Essential Medicines (2021) | 12.4. Medicines used in heart failure |
Others observations: Therapeutic alternatives: 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain). |
List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines |
Others observations: Losartan can be used as an alternative for treatment of adults with hypertension for those patients in whom ACEi are indicated but not tolerated, specifically due to the presence of adverse events (mainly cough); including the sub-population of hypertensive patients associated with type II diabetes with proteinuria. |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) |
WHO Model List of Essential Medicines (2021) | 12.4. Medicines used in heart failure |
Others observations: Therapeutic alternatives: 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain). |